- Home
- ALDX vs WEA Comparison
ALDX vs WEA Comparison
Compare ALDX & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- WEA
- Stock Information
- Founded
- ALDX 2004
- WEA 2002
- Country
- ALDX United States
- WEA United States
- Employees
- ALDX N/A
- WEA N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- WEA Trusts Except Educational Religious and Charitable
- Sector
- ALDX Health Care
- WEA Finance
- Exchange
- ALDX Nasdaq
- WEA Nasdaq
- Market Cap
- ALDX 133.7M
- WEA 129.0M
- IPO Year
- ALDX 2014
- WEA N/A
- Fundamental
- Price
- ALDX $2.17
- WEA $10.60
- Analyst Decision
- ALDX Strong Buy
- WEA
- Analyst Count
- ALDX 2
- WEA 0
- Target Price
- ALDX $9.50
- WEA N/A
- AVG Volume (30 Days)
- ALDX 1.2M
- WEA 46.1K
- Earning Date
- ALDX 05-14-2025
- WEA 01-01-0001
- Dividend Yield
- ALDX N/A
- WEA 7.87%
- EPS Growth
- ALDX N/A
- WEA N/A
- EPS
- ALDX N/A
- WEA N/A
- Revenue
- ALDX N/A
- WEA N/A
- Revenue This Year
- ALDX N/A
- WEA N/A
- Revenue Next Year
- ALDX N/A
- WEA N/A
- P/E Ratio
- ALDX N/A
- WEA N/A
- Revenue Growth
- ALDX N/A
- WEA N/A
- 52 Week Low
- ALDX $1.14
- WEA $9.60
- 52 Week High
- ALDX $7.20
- WEA $11.29
- Technical
- Relative Strength Index (RSI)
- ALDX 38.93
- WEA 55.09
- Support Level
- ALDX $2.10
- WEA $10.56
- Resistance Level
- ALDX $2.30
- WEA $10.71
- Average True Range (ATR)
- ALDX 0.15
- WEA 0.12
- MACD
- ALDX 0.06
- WEA 0.02
- Stochastic Oscillator
- ALDX 37.93
- WEA 100.00
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.